Ernexa Therapeutics Inc. ERNA
are a preclinical-stage synthetic allogeneic iMSC therapy company. iMSCs are induced pluripotent stem cell ("iPSC")-derived
mesenchymal stem cells. We envision a future where cell therapies powered by synthetic iMSCs can offer new options for patients with
limited treatment paths and our mission is to transform the treatment of cancer and autoimmune disease by developing scalable, affordable,
off-the-shelf cell therapies that restore hope.
Last close
4.31
2026-09-04
Market cap
$7.0M
2026-06-30 share count
52-week range
3.18 - 71.50
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-2.24
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $582.0K | $68.0K | $0 | — | $5.8M | $19.8M | $23.3M | $21.3M | $22.3M |
| Cost of revenue | — | $96.0K | $236.0K | $0 | — | — | — | — | — | — |
| Gross profit | — | $486.0K | -$168.0K | $0 | — | — | — | — | — | — |
| R&D | — | — | — | — | — | $2.0K | $26.0K | $72.0K | $139.0K | — |
| SG&A | $5.2M | $13.1M | $14.6M | $16.8M | $14.7M | $3.3M | $13.2M | $14.5M | $15.6M | $16.5M |
| Total operating expenses | $9.3M | $16.2M | $21.0M | $33.2M | $113.7M | $7.2M | $21.6M | $23.1M | $22.7M | $24.6M |
| Operating income | -$9.3M | -$15.7M | -$21.1M | -$33.2M | -$113.7M | -$7.2M | -$1.8M | $203.0K | -$1.4M | -$2.3M |
| Interest expense | $100.0K | $6.8M | $500.0K | $30.0K | — | — | — | — | — | — |
| Pre-tax income | -$14.1M | -$44.5M | -$21.7M | -$24.5M | -$122.5M | -$7.3M | -$2.0M | -$323.0K | -$1.0M | -$2.9M |
| Income tax | $45.0K | $30.0K | $3.0K | $45.0K | $64.0K | $0 | $27.0K | $64.0K | $66.0K | $38.0K |
| Net income | -$14.1M | -$44.5M | -$21.7M | -$24.6M | -$122.5M | -$7.3M | -$2.0M | -$259.0K | -$1.1M | -$2.9M |
| EPS, basic | -2.24 | -48.96 | -4.08 | -8.06 | -56.61 | -0.41 | — | — | — | — |
| EPS, diluted | -2.24 | -48.96 | -4.08 | -8.06 | -56.61 | -0.41 | -0.72 | -0.10 | -0.45 | -1.54 |
| Shares, diluted (wtd. avg.) | $6.3M | $910.0K | $5.3M | $3.1M | $2.2M | $17.6M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.9M | $1.7M | $11.7M | $15.5M | $17.0M | $1.6M | $5.1M | $2.5M | $3.4M | $5.7M |
| Receivables | — | — | — | — | $684.0K | $0 | $1.2M | $1.1M | $714.0K | $928.0K |
| Total current assets | $3.1M | $2.4M | $9.6M | $13.7M | $18.8M | $1.7M | $6.1M | $6.8M | $9.6M | $10.7M |
| Property, plant and equipment | $94.0K | $85.0K | $493.0K | $236.0K | $670.0K | $594.0K | $2.8M | $4.7M | $3.7M | $3.1M |
| Goodwill | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M | $696.0K | $667.0K | $1.0M | $937.0K |
| Other intangibles | — | — | — | — | — | — | $696.0K | $667.0K | $1.0M | $29.0K |
| Total assets | $5.8M | $5.3M | $49.1M | $22.3M | $31.5M | $12.9M | $14.1M | $14.9M | $16.6M | $16.7M |
| Accounts payable | $1.1M | $1.7M | $1.1M | $1.6M | $1.8M | $1.3M | $835.0K | $271.0K | $390.0K | $247.0K |
| Short-term debt | — | — | — | — | — | $1.5M | $2.7M | $1.0M | $5.1M | $3.0M |
| Total current liabilities | $3.1M | $2.9M | $6.6M | $7.7M | $3.7M | $3.1M | $6.1M | $4.0M | $10.7M | $6.6M |
| Long-term debt | — | — | — | — | — | $532.0K | — | $3.8M | $5.1M | $8.1M |
| Total liabilities | $3.4M | $3.6M | $46.9M | $10.2M | $6.0M | $5.2M | $9.0M | $7.9M | $11.0M | $12.6M |
| Retained earnings | -$245.6M | -$231.5M | -$187.0M | -$165.3M | -$140.7M | -$18.1M | -$131.5M | -$129.4M | -$129.1M | -$128.0M |
| Total equity | $2.4M | $1.7M | $2.2M | $12.1M | $25.5M | $7.7M | $9.7M | $6.9M | $5.5M | $4.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.0M | -$15.8M | -$20.4M | -$21.0M | -$23.5M | -$8.1M | $2.7M | $1.4M | $549.0K | $23.0K |
| Depreciation and amortisation | $65.0K | $139.0K | $84.0K | $161.0K | $117.0K | $98.0K | $2.4M | $2.8M | $2.3M | $2.9M |
| Stock-based compensation | $1.5M | $1.5M | $1.2M | $2.9M | $5.2M | $91.0K | $206.0K | $443.0K | $457.0K | $419.0K |
| Capital expenditure | $37.0K | $369.0K | $19.0K | $297.0K | $154.0K | $39.0K | $966.0K | $648.0K | $728.0K | $427.0K |
| Investing cash flow | -$37.0K | -$365.0K | -$19.0K | -$47.0K | -$22.7M | -$39.0K | -$1.1M | -$1.6M | -$1.5M | -$840.0K |
| Financing cash flow | $7.2M | $6.3M | $16.6M | $19.6M | $61.6M | $4.7M | -$1.1M | -$303.0K | -$1.5M | $3.3M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-022281.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |